Episodes

  • Highlights From ISC 2026: Insights Into Secondary Stroke Prevention From the OCEAN-STROKE Trial

    Highlights From ISC 2026: Insights Into Secondary Stroke Prevention From the OCEAN-STROKE Trial
    Apr 2 2026
    Drs. Sanossian and Saver review new evidence supporting intensified antithrombotic strategies to reduce recurrent ischemic stroke in high-risk, noncardioembolic patients without increasing intracranial hemorrhage. They place this within a comprehensive, multimodal secondary prevention framework that integrates pharmacologic therapy with aggressive risk factor modification (lipids, blood pressure, diabetes, and lifestyle).
    Show more Show less
    9 mins
  • CLL at ASH 2025: CLL17

    CLL at ASH 2025: CLL17
    Apr 2 2026
    Drs. O’Brien and Wierda discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.
    Show more Show less
    9 mins
  • Neuromodulation in Migraine Care: Insights From the 2025 IHS Guidelines

    Neuromodulation in Migraine Care: Insights From the 2025 IHS Guidelines
    Mar 31 2026
    Drs. Dougherty and Ailani discuss the 2025 International Headache Society guidelines indicating that neuromodulation is an effective, non-invasive option for both acute and preventive migraine treatment. They stress that it works best as part of a personalized, multimodal plan alongside medications, behavioral therapies, and lifestyle changes.
    Show more Show less
    6 mins
  • Diagnosing Obstructive Hypertrophic Cardiomyopathy: Key Considerations for Clinicians

    Diagnosing Obstructive Hypertrophic Cardiomyopathy: Key Considerations for Clinicians
    Mar 30 2026
    Drs. Maron and Rowin provide an overview of hypertrophic cardiomyopathy, explaining how it is diagnosed by heart imaging and classified into obstructive and non-obstructive forms. They highlight that obstruction is a major cause of symptoms and stress the importance of carefully assessing patients’ day-to-day limitations to guide treatment decisions.
    Show more Show less
    9 mins
  • ACR 2025: Risk of Proteinuria in Patients With Lupus Nephritis and the Timing of Kidney Biopsy in Patients With SLE

    ACR 2025: Risk of Proteinuria in Patients With Lupus Nephritis and the Timing of Kidney Biopsy in Patients With SLE
    Mar 27 2026
    Drs. Petri and Woolfson discuss a simple risk score using autoantibodies, complement, and demographics to predict which SLE patients are most likely to develop proteinuria and lupus nephritis. They also highlight evidence showing that earlier kidney biopsies at lower proteinuria levels, especially in patients with low complement, can detect serious disease sooner and improve outcomes.
    Show more Show less
    8 mins
  • Could anticoagulant choice cut bleeding risk in half for patients with acute VTE?

    Could anticoagulant choice cut bleeding risk in half for patients with acute VTE?
    Mar 26 2026
    This week's podcast covers three NEJM trials. First, apixaban showed over 50% less clinically relevant bleeding than rivaroxaban in acute venous thromboembolism patients, with similar efficacy. Second, romiplostim helped 84% of patients on oxaliplatin-based chemotherapy avoid dose modifications due to thrombocytopenia, versus 36% with placebo. Third, inhaled treprostinil slowed lung function decline in idiopathic pulmonary fibrosis patients over 52 weeks, though cough and discontinuation rates were higher.
    Show more Show less
    4 mins
  • 2025 San Antonio Breast Cancer Symposium: Evolving First-Line Approaches in Metastatic HER2+ Breast Cancer

    2025 San Antonio Breast Cancer Symposium: Evolving First-Line Approaches in Metastatic HER2+ Breast Cancer
    Mar 25 2026
    Drs. Isaacs and Traina discuss DESTINY-Breast09, where first‑line T‑DXd + pertuzumab clearly outperforms the CLEOPATRA regimen in progression-free survival for metastatic HER2+ breast cancer. They focus on the dilemma of when to use T‑DXd: earlier, for maximal efficacy, or later, to protect quality of life and manage ILD and cardiac risks.
    Show more Show less
    11 mins
  • Could personalized breast screening replace annual mammograms?

    Could personalized breast screening replace annual mammograms?
    Mar 24 2026
    This week's podcast covers three NEJM trials. First, apixaban showed over 50% less clinically relevant bleeding than rivaroxaban in acute venous thromboembolism patients, with similar efficacy. Second, romiplostim helped 84% of patients on oxaliplatin-based chemotherapy avoid dose modifications due to thrombocytopenia, versus 36% with placebo. Third, inhaled treprostinil slowed lung function decline in idiopathic pulmonary fibrosis patients over 52 weeks, though cough and discontinuation rates were higher.
    Show more Show less
    5 mins